LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS

Information

  • Research Project
  • 6374647
  • ApplicationId
    6374647
  • Core Project Number
    R01AI048297
  • Full Project Number
    5R01AI048297-02
  • Serial Number
    48297
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2000 - 24 years ago
  • Project End Date
    3/31/2003 - 21 years ago
  • Program Officer Name
    MEEGAN, JAMES M.
  • Budget Start Date
    4/1/2001 - 23 years ago
  • Budget End Date
    3/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/31/2001 - 23 years ago
Organizations

LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS

DESCRIPTION: (Adapted from Applicant's Abstract) West Nile (WN) virus emerged as an epidemic disease of humans, horses, and birds in the U.S. in 1999, and there is a significant risk of recrudescent outbreaks in the future. This application proposes to develop a parenteral vaccine for all affected species (humans, horses, and domestic and exotic birds) by constructing a chimeric virus in which the envelope genes of yellow fever (YF) 17D vaccine are replaced with the corresponding genes of WN virus. The E gene of WN virus will be mutated at specific sites to render the vaccine candidate safe. The resulting live, attenuated YF/WN chimeric viral vaccine will elicit rapid and durable immunity specific for WN virus. The potential for oral delivery of the vaccine as a means of immunizing birds will also be investigated. Preclinical data in Phase I will be followed by process development, manufacturing of clinical grade vaccine and clinical trials in humans, horses, and birds in Phase II. In Phase II a live oral bait vaccine based on Salmonella typhimurium that expresses WN viral proteins or plasmids will be developed for immunizing wild birds involved in natural transmission, as a means of interrupting virus transmission in nature and prevention of epidemics.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1111767
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:1111767\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACAMBIS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES